California Jury Awards $2 Billion to Plaintiffs in Roundup Case

May 16, 2019
Worker Applying Weed Killer600x450

A California jury has delivered yet another significant blow to Monsanto, the company that manufactures Roundup weed killer. On May 13, 2019, an Oakland jury awarded $2 billion to a California couple who claimed they developed cancer after using Roundup. This is the third jury to conclude that the company failed to warn consumers of the dangers associated with the use of the weed killer. Thousands of additional lawsuits against Monsanto, which was purchased by Bayer last year, are still pending in state and federal court.

The Pressure Mounts

The plaintiffs in the case used Roundup around their home for more than 30 years. The husband was diagnosed with non-Hodgkin’s lymphoma in 2011 and his wife was diagnosed in 2015. Thankfully, both are now in remission.

Monsanto is alleged to have tried to manipulate studies on glyphosate in order to make it seem that the chemical is safe to use. However, the World Health Organization’s International Agency for Research on Cancer said in 2015 that glyphosate was probably cancerous to humans.

Other recent cases involved plaintiffs who also developed the disease after being exposed to glyphosate, the active ingredient in Roundup. Plaintiffs in those cases won verdicts totaling more than $150 million.

The Roundup verdicts have battered Bayer’s stocks which have fallen over 40% since it acquired Monsanto. Bayer has stated it plans to appeal the $2 billion verdict.

Contact Baron & Budd

Please contact Baron & Budd if you developed non-Hodgkin’s lymphoma after exposure to Roundup, or if someone you know was diagnosed with the disease after using the product. Contact us online or call 866-723-1890 to learn more about how we may be able to help you obtain compensation.

News Articles

View All

  • Get Answers Now

    Get a free case evaluation to help determine your legal rights.

  • Receive emails from Baron & Budd?
  • Receive text messages from Baron & Budd?
  • This field is for validation purposes and should be left unchanged.